Pear Therapeutics Launches Somryst for the Treatment of Chronic Insomnia

Pear Therapeutics, Inc., recently announced the availability of Somryst™, the first prescription digital therapeutic (PDT) intended for use in the treatment of patients 22 years of age and older with chronic insomnia.